author-photo

Dorothy Romanus

Takeda Pharmaceutical Company

44

Papers

232

Citations

Citation Trend

Filter By

Papers (29) Sort By

Journal Conference Others

Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain.

2021 Future Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US.

2021 Annals of Hematology
Show All
- Source
- Cite
- Save
Citations (0)
Treatment Satisfaction and Burden of Illness in Patients with Newly Diagnosed Multiple Myeloma

2019
Show All
- Source
- Cite
- Save
Citations (5)
HEALTH-RELATED QUALITY OF LIFE (HRQOL) OUTCOMES OF ORAL IXAZOMIB MAINTENANCE THERAPY POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) FROM TOURMALINE-MM3: PF626

2019
Show All
- Source
- Cite
- Save
Citations (0)
Patient‐Reported Factors in Treatment Satisfaction in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

2019 Oncologist
Show All
- Source
- Cite
- Save
Citations (12)
CHARACTERISTICS AND TREATMENT OUTCOMES OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) NON-STEM CELL TRANSPLANT (NSCT) PATIENTS IN THE UK, GERMANY, AND FRANCE: PS1411

2019
Show All
- Source
- Cite
- Save
Citations (0)
Estimating the Global Epidemiology of Amyloid Light-Chain Amyloidosis With an Incidence-to-Prevalence Model

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
PCN242 APPROACHES TO PRAGMATIC METHODOLOGY IN ONCOLOGY RETROSPECTIVE STUDIES

2019 Value in Health
Show All
- Source
- Cite
- Save
Citations (0)
Randomized Clinical Trial Representativeness and Outcomes in Real-World Patients: Comparison of 6 Hallmark RCTs in Relapsed/Refractory Multiple Myeloma

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (30)
Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

2019 Blood
Show All
- Source
- Cite
- Save
Citations (1)